Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Erika Yanil Faraoni

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0731-2122; OpenAlex author ID A5022792492. Sources: OpenAlex.

Their work

Papers
10 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: 4 papers · 2025: none · 2026: 1 paper

Papers 10

  1. Dietary Fat Content Influences PanIN Progression and Pancreatic Cancer Development in Mice. First author DOI 10.1158/2767-9764.crc-25-0777↗
  2. EUS-guided radiofrequency ablation for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.gie.2024.04.2926↗
  3. Gastric cancer prevention and screening during pancreatic cancer screening in high-risk individuals: an opportunity not to be missed First author DOI 10.1016/j.gie.2024.12.001↗
  4. Increased Gremlin1 Expression in Pancreatic Ductal Adenocarcinoma Promotes a Fibrogenic Stromal Microenvironment. First author DOI 10.1097/mpa.0000000000002378↗
  5. Unlocking the Pancreatic Cancer Puzzle: Using Intermediate Cells to Target Treatment. Co-author DOI 10.1158/1078-0432.ccr-23-3295↗
  6. CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-2553↗
  7. Radiofrequency Ablation Remodels the Tumor Microenvironment and Promotes Neutrophil-Mediated Abscopal Immunomodulation in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-22-0379↗
  8. The resurgence of the Adora2b receptor as an immunotherapeutic target in pancreatic cancer. First author DOI 10.3389/fimmu.2023.1163585↗
  9. Radiofrequency ablation in combination with CD73 inhibitor AB680 reduces tumor growth and enhances anti-tumor immunity in a syngeneic model of pancreatic ducta… Co-author DOI 10.3389/fonc.2022.995027↗
  10. Pancreatic cancer ductal cell of origin drives CD73-dependent generation of immunosuppressive adenosine First author DOI 10.1101/2021.11.29.470415↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jennifer M. Bailey · 8 shared papers, 2021–2026 · strength 1.47
  2. Florencia M. McAllister · 5 shared papers, 2021–2026 · strength 1.29
  3. Lincoln N. Strickland · 5 shared papers, 2022–2026 · strength 0.97
  4. Curtis Jackson Wray · 5 shared papers, 2021–2024 · strength 0.76
  5. Nirav C Thosani · 5 shared papers, 2021–2024 · strength 0.76
  6. Putao Cen · 2 shared papers, 2023–2024 · strength 0.37
  7. Maureen E. Mork · 1 shared paper, 2024 · strength 0.31
  8. Manoop S. Bhutani · 1 shared paper, 2024 · strength 0.31
  9. Urvinder Kaur Sardarni · 1 shared paper, 2026 · strength 0.30
  10. Jesse L. Cox · 1 shared paper, 2026 · strength 0.30
  11. Dafna Bar‐Sagi · 2 shared papers, 2021–2023 · strength 0.22
  12. Powel H. Brown · 2 shared papers, 2021–2023 · strength 0.22
  13. Kanchan Singh · 2 shared papers, 2021–2023 · strength 0.22
  14. Vidhi Chandra · 2 shared papers, 2021–2023 · strength 0.22
  15. Altaf Mohammed · 2 shared papers, 2021–2023 · strength 0.22
  16. George Van Buren · 2 shared papers, 2021–2023 · strength 0.22
  17. Rachel R. Tindall · 1 shared paper, 2024 · strength 0.19
  18. Tien C. Ko · 1 shared paper, 2024 · strength 0.19
  19. Mamoun Younes · 1 shared paper, 2024 · strength 0.19
  20. Le Li · 1 shared paper, 2023 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.